In line with these results, in pancreatic ductal adenocarcinoma high OXCT1 expression correlated with short relapse-free survival upon gemcitabine treatment; its overexpression decreased apoptosis upon gemcitabine exposure, while OXCT1 knockdown reversed resistance [34]. Here, OXCT1 is linked to pancreatic ductal adenocarcinoma.